2025 Alzheimer's Treatment Roadmap From Prevention to Severe Dementia

Alzheimer's disease (AD) affects tens of millions globally, and the US National Alzheimer's Project Act of 2011 set a goal of developing effective treatments by 2025. This review, authored by neurologists at Brown University and National Yang Ming Chiao Tung University, argues that goal has been substantially met—with important caveats—and provides a clinical roadmap for the current treatment era.

The historical arc of AD treatment began with tacrine's FDA approval in 1993, the first cholinesterase inhibitor (ChEI), which established the template for AD drug trials including standardized diagnostic criteria, the Alzheimer's Disease Assessment Scale (ADAS), and the Clinical Global Impression of Change. Three additional ChEIs (donepezil 1996, rivastigmine 2000, galantamine 2001) and memantine (2003) followed. These agents provide symptomatic benefit and functional stabilization but do not alter the underlying pathology.

The pivotal shift came with the development of amyloid PET tracers (arriving ~2012) and the subsequent identification of early-stage AD as the optimal therapeutic window. This culminated in FDA approval of lecanemab (2023) and donanemab (2024), monoclonal antibodies that clear amyloid plaques and demonstrably slow cognitive decline in MCI and mild dementia when confirmed by biomarkers. The review presents a conceptual figure showing that untreated mild AD dementia progresses to severe dementia in ~3 years; ChEIs extend adequate cognitive function to 5–8 years; adding anti-amyloid therapy to ChEI may extend this further to 5–10 years, with the aspiration that future disease-modifying agents will sustain near-normal cognition in presymptomatic individuals.

A new six-stage diagnostic framework published in 2024 underpins treatment planning: Stage 1 (asymptomatic, biomarker-positive), Stage 2 (subjective cognitive decline with normal testing but positive biomarkers), Stage 3 (MCI), Stage 4 (mild dementia), Stage 5 (moderate dementia), Stage 6 (severe dementia). FDA-approved therapies exist for Stages 3–6. Anti-amyloid and anti-tau trials are actively enrolling Stage 1–2 participants. Plasma biomarkers such as p-tau217 and Aβ42/40 offer a scalable, cost-effective complement to PET and CSF assays for staging, particularly in resource-limited settings. Several tau-targeting agents (semorinemab, zagotenemab, BIIB080) are in trials but none yet approved.

Beyond pharmacology, the review emphasizes multimodal, personalized care: aerobic exercise, cognitive training, vascular risk factor management, dietary optimization, and structured caregiver support. These interventions are particularly relevant for Stages 1–2 where no approved drugs exist. The authors acknowledge significant access barriers—amyloid PET and CSF biomarkers remain expensive and infrastructure-limited in many regions—and stress that optimizing conventional ChEI/memantine use and expanding basic diagnostic access are global imperatives alongside cutting-edge immunotherapy rollout.